Article
Concentration‐dependent metabolic effects of metformin in healthy and Fanconi anemia lymphoblast cells
6 Jul 2017
Abstract excerpt
Metformin (MET) is the drug of choice for patients with type 2 diabetes and has been proposed for use in cancer therapy and for treating other metabolic diseases. More than 14,000 studies have been published addressing the cellular mechanisms affected by MET. However, several in vitro studies have used concentrations of the drug 10-100-fold higher than the plasmatic concentration measured in patients. Here, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
